clinical trial · NCT06864169
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Merck Sharp & Dohme LLC·phase2·active not recruiting·n = 160
Gastrointestinal CancerRaludotatug Deruxtecan (R-DXd)
brief summary
Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).
started
Apr 1, 2025
primary completion
Aug 18, 2026
completion
Jan 4, 2029
last updated
Apr 23, 2026
official title
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol